Skip to content
Screener

Innoviva, Inc. INVA Other operating expenses

Other operating expenses at other companies

Insmed logo
InsmedINSM
-0.1%
Savara logo
SavaraSVRA
$38.99M+37.1%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$46.11M-30.9%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$27.18M-8.9%
Pulmonx Corporation logo
Pulmonx CorporationLUNG
$29M-6.2%
Zymeworks logo
ZymeworksZYME
-$3.11M-211%

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.53B+33.1%
Enterprise value$1.22B+2.1%
P/E4.3×-25.4×
P/S3.5×+0.4×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Operating expenses:
Selling, general and administrative34,57126,41267,00953,903
Research and development5,1907,98310,43112,379
Total operating expenses39,76134,39577,44066,282
Income from operations50,85548,75189,00990,179
Changes in fair values of equity method investments, net(131,834)13,08225,816(467)
Changes in fair values of equity and long-term investments, net(29,153)11,2804,422(54,019)
Interest and dividend income7,5994,92518,5869,463

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s other operating expenses?
Innoviva, Inc. (INVA) reported other operating expenses of $39.76M in Q2 2026.
How has Innoviva, Inc.'s other operating expenses changed year-over-year?
Innoviva, Inc.'s other operating expenses increased by 15.6% year-over-year, from $34.4M to $39.76M.
What is the long-term trend for Innoviva, Inc.'s other operating expenses?
Over 3 years (2021 to 2025), Innoviva, Inc.'s other operating expenses has grown at a 10.6% compound annual growth rate (CAGR), from $106.35M to $143.92M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.

Ask your AI about Innoviva, Inc.'s other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude